SAN DIEGO and
TORONTO, Oct. 21, 2014 /PRNewswire/ - Aptose Biosciences
Inc. (Aptose) (TSX:APS), a clinical-stage company developing
targeted agents and molecular diagnostics to treat the underlying
mechanisms of cancer, announced today that its common shares have
been approved for listing on the NASDAQ Capital Market under the
symbol "APTO".
Aptose will begin trading on NASDAQ on or around
October 23, 2014. The Company will
retain its listing on the Toronto Stock Exchange under the symbol
"APS".
"Our listing on the NASDAQ Capital Market is a
major milestone for the company and a testament to the significant
progress Aptose has achieved in the past year," said William G. Rice, Ph.D., Aptose's Chairman,
President and Chief Executive Officer. "Moving forward, we
believe the listing will provide access to a broader range of
investors and opportunity for increased shareholder value."
About Aptose
Aptose Biosciences is a clinical-stage
biotechnology company committed to discovering and developing
personalized therapies addressing unmet medical needs in oncology.
Aptose is advancing new therapeutics focused on novel cellular
targets on the leading edge of cancer research coupled with
companion diagnostics to identify the optimal patient population
for our products. The company's small molecule cancer therapeutics
pipeline includes products designed to provide additive or
synergistic efficacy with existing anti-cancer therapies and
regimens without overlapping toxicities. Aptose Biosciences Inc. is
listed on the TSX under the symbol APS and will be listed on NASDAQ
under the symbol APTO.
This press release contains forward-looking
statements within the meaning of Canadian and U.S. securities laws.
Such statements include, but are not limited to, statements
relating to Aptose's plans, objectives, expectations and intentions
and other statements including words such as "continue", "expect",
"intend", "will", "should", "would", "may", and other similar
expressions and including, without limitation, statements regarding
the listing date of Aptose's common shares on NASDAQ and the
expected benefits to be derived from the listing. Such statements
reflect our current views with respect to future events and are
subject to risks and uncertainties and are necessarily based upon a
number of estimates and assumptions that, while considered
reasonable by us are inherently subject to significant business,
economic, competitive, political and social uncertainties and
contingencies. Many factors could cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements described in this press
release. Such expressed or implied factors include, among others:
changes in our stock price; our ability to meet listing
requirements; our ability to obtain the capital required for
research and operations; the inherent risks in early stage drug
development including demonstrating efficacy; development time/cost
and the regulatory approval process; the progress of our clinical
trials; our ability to find and enter into agreements with
potential partners; our ability to attract and retain key
personnel; changing market conditions; stock market volatility; and
other risks detailed from time-to-time in our ongoing quarterly
filings, annual information forms, annual reports and annual
filings with Canadian securities regulators and the United States
Securities and Exchange Commission.
Should one or more of these risks or
uncertainties materialize, or should the assumptions set out in the
section entitled "Risk Factors" in our filings with Canadian
securities regulators and the United States Securities and Exchange
Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described
herein. These forward-looking statements are made as of the date of
this press release and we do not intend, and do not assume any
obligation, to update these forward-looking statements, except as
required by law. We cannot assure you that such statements will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements
due to the inherent uncertainty therein.
SOURCE Aptose Biosciences Inc.
PDF available at:
http://stream1.newswire.ca/media/2014/10/21/20141021_C9026_DOC_EN_43076.pdf
